# Strategic Feedback — GPT-5.4 (R1)

**Role:** Journal editor (AER perspective)
**Model:** openai/gpt-5.4
**Timestamp:** 2026-03-27T14:18:25.207773
**Route:** OpenRouter + LaTeX
**Tokens:** 9112 in / 3680 out
**Response SHA256:** 3939f33a89d0b105

---

## 1. THE ELEVATOR PITCH

This paper asks whether fentanyl test strip legalization reduces overdose deaths through the specific mechanism of information revelation. Rather than estimating another aggregate policy effect, it compares overdose mortality across drug types with high versus low risk of fentanyl contamination to ask a sharper question: do test strips help most where they plausibly provide new information?

A busy economist should care because this is, in principle, a nice example of moving from “does the policy work on average?” to “through what channel would it work?” That is exactly the kind of move that can elevate a policy evaluation from descriptive treatment effects to something more general about behavior under risk and information.

Does the paper itself articulate this pitch clearly in the first two paragraphs? Not quite. The introduction is competent, but it takes too long to get to the real idea, and it undersells the paper by sounding like a narrow harm-reduction paper with a null result. The actual intellectual hook is the mechanism test. That should appear immediately.

### The pitch the paper should have

“Fentanyl test strips are supposed to save lives by revealing hidden contamination in illicit drugs. But existing evidence asks only whether legalization changes overdose deaths on average, not whether deaths fall precisely where information should matter most. This paper uses variation in fentanyl contamination risk across drug types to test the core mechanism: if test strips work through information, mortality should fall more for heroin and cocaine than for drugs like methadone that are not exposed to street-level contamination.

Using state-by-year-by-drug mortality data and the staggered legalization of fentanyl test strips across states, I estimate whether legalization narrows the mortality gap between high- and low-contamination drugs. The central result is sobering: the differential effect is directionally negative but imprecise, while a methadone ‘negative control’ moves in the wrong direction, suggesting that test strip legalization is bundled with broader harm-reduction expansion. The contribution is therefore not just another estimate of a policy effect, but a mechanism-based test showing how hard it is to isolate the informational value of a harm-reduction tool in real-world policy bundles.”

That is the opening. Right now the introduction begins with the crisis, then the policy, then the literature. It should begin with the mechanism and why aggregate estimates are inadequate.

---

## 2. CONTRIBUTION CLARITY

### One-sentence contribution

The paper’s contribution is to use drug-type heterogeneity in fentanyl contamination risk to test whether fentanyl test strip legalization reduces overdose mortality through an information-revelation channel rather than merely estimating an aggregate policy effect.

### Is this clearly differentiated from the closest papers?

Only partly. The paper differentiates itself from “aggregate DiD on FTS legalization” and from public-health papers on distribution and uptake, but it does not yet make the distinction feel sharp enough. Right now the contribution still risks sounding like: “another staggered-policy paper, but with a DDD and some negative controls.”

To stand out, the paper has to say much more crisply:

- prior papers estimate average effects of legalization;
- this paper asks whether the pattern of effects across drugs matches the policy’s core mechanism;
- the answer matters even if aggregate mortality effects are small or zero.

That last point is essential. Mechanism is the contribution; the policy estimate is secondary.

### Is the contribution framed as a question about the world or a gap in a literature?

Mostly a literature gap. That weakens it. The stronger framing is a world question:

- When policymakers legalize a cheap information technology in a contaminated illicit market, does it save lives by changing behavior where information is scarce?

That is broader and more durable than “there is no paper yet using a triple-difference drug-type decomposition.”

### Could a smart economist explain what is new after reading the intro?

Not confidently. They might say: “It’s a DiD/DDD paper on fentanyl test strips, with null-ish results and a methadone control.” That is not enough.

What you want them to say is: “It tests the mechanism rather than just the mean effect, by asking whether the policy matters only for drugs that users might unknowingly consume with fentanyl.”

Right now that idea is there, but not branded hard enough.

### What would make the contribution bigger?

Specific ways to enlarge it:

1. **Frame it as a general design for mechanism testing in bundled policies.**  
   The methadone result is potentially the most interesting part of the paper, but the paper treats it as a side diagnostic. It could instead be central: policy bundles confound mechanism inference, and within-policy negative controls can reveal that.

2. **Lean harder into substitution/composition outcomes, not just mortality.**  
   If the contribution is about information revelation, then mortality is a very distal outcome. Bigger contribution if the paper could connect to behavior more directly: emergency department visits, naloxone administrations, treatment entry, or shifts across drug categories. Even without adding data, the paper should acknowledge that mortality is an equilibrium endpoint and mechanism tests are therefore inherently difficult.

3. **Make the comparison sharper conceptually.**  
   The current high- vs low-contamination grouping is intuitive but somewhat ad hoc. A bigger paper would either use a contamination-risk continuum or tie drug categories more explicitly to ex ante user uncertainty.

4. **Broaden the underlying economic question.**  
   This could be a paper about information in credence/experience goods under extreme risk, not only about fentanyl policy.

If they could enlarge only one dimension, it should be conceptual: from “FTS legalization and overdose deaths” to “how to test behavioral mechanisms of information policies when treatment is bundled with complementary interventions.”

---

## 3. LITERATURE POSITIONING

### Closest neighbors

Some of the exact citations in the paper look placeholder-ish or difficult to verify, but the relevant neighboring conversations are fairly clear. The closest neighbors are likely:

1. **The emerging economics literature on harm reduction and overdose policy**  
   e.g., work by Doleac, Dave, Maclean, and coauthors on naloxone access laws, Good Samaritan laws, syringe exchange, and opioid policy.

2. **The public health literature on fentanyl test strips and drug checking**  
   studies documenting uptake, behavioral response, and user-reported changes after positive tests.

3. **The recent literature on staggered adoption / policy evaluation with heterogeneous treatment timing**  
   though this is not where the paper should lead.

4. **The older economics literature on mechanism-oriented reduced-form design / triple differences**  
   Gruber-style DDD as a way of isolating channels through within-unit comparisons.

5. **A broader information-and-risk literature**  
   where agents respond to noisy signals about product quality or hidden danger.

### How should the paper position itself relative to those neighbors?

- **Build on aggregate FTS legalization papers**, not attack them. The right line is: aggregate mortality effects are an important first step, but they cannot test the policy’s mechanism.
- **Borrow credibility from public health evidence on user behavior**, but distinguish by saying those papers establish plausibility of micro responses, not population mortality effects.
- **Do not overplay the econometric novelty.** The DDD is a tool, not the contribution.
- **Potentially synthesize harm reduction and information economics.** That would give the paper a broader audience.

### Is it currently positioned too narrowly or too broadly?

Too narrowly in topic, too broadly in method.

- Too narrowly because it reads like a specialized paper for drug-policy people.
- Too broadly in the sense that it claims contributions to econometrics and public health in a diffuse way that does not feel earned by the scale of the exercise.

The right audience is: applied micro economists interested in information, health, and policy design. The paper should not pretend to be a contribution to econometric method. It is an application of a standard design to a mechanism question.

### What literature does the paper seem unaware of?

It needs stronger engagement with:

- **Information provision and salience in health behavior**
- **Technology adoption under risk**
- **Policy bundling / complementarity in public interventions**
- **Negative controls and falsification logic in applied work**, though again not as a methods paper
- Possibly **drug checking and market quality uncertainty** from public health and criminology

The surprising methadone result especially cries out for conversation with work on treatment expansion, medication-assisted treatment, and the unintended consequences/compositional consequences of harm-reduction packages.

### Is the paper having the right conversation?

Not yet. The current conversation is: “Does FTS legalization reduce overdose deaths, and what happens by drug type?” The more impactful conversation is: “When a policy’s theory of change is information, how can we tell whether observed effects actually reflect information rather than correlated policy change?”

That is the conversation top general-interest economists are more likely to care about.

---

## 4. NARRATIVE ARC

### Setup

The world before this paper: fentanyl test strips spread rapidly as a harm-reduction innovation; many states legalize them; some evidence examines aggregate mortality effects; public-health studies show users say they change behavior after positive tests.

### Tension

The tension should be: aggregate policy effects do not tell us whether the strips work through their intended mechanism. If they are informational tools, effects should be concentrated where users face uncertainty about fentanyl contamination. But legalization occurs inside a broader harm-reduction policy package, making mechanism inference hard.

### Resolution

The paper finds a directionally negative but imprecise differential effect for high-contamination drugs, and a methadone negative control that moves positively. The implied resolution is not “FTS do nothing,” but “the data do not cleanly support a distinct information-revelation mortality channel, and bundled policy change may confound simple interpretations.”

### Implications

The implications are potentially interesting:

- policymakers should be cautious in interpreting legalization as proof of mortality impact;
- researchers should distinguish legal availability from actual use and from complementary service expansion;
- mechanism tests can reveal confounding that average treatment effects hide.

### Does the paper have a clear narrative arc?

Serviceable, but not strong. It currently feels somewhat like a collection of sensible exercises arranged around a DDD estimate. The methadone result is the most narratively alive piece, but it arrives too late and is treated too defensively.

### What story should it be telling?

The story should be:

1. FTS are an information technology.
2. Information should matter only where contamination risk is uncertain and heterogeneous.
3. Therefore, comparing high- and low-contamination drugs is the right mechanism test.
4. The mechanism test is weakly supportive at best.
5. The negative control suggests why: legalization is not a standalone treatment but a marker for a broader harm-reduction package.
6. Hence the real lesson is about the difficulty of learning the effect of a single informational intervention from legal changes alone.

That is a coherent AER-type narrative. Right now the paper almost tells it, but not with enough discipline.

---

## 5. THE “SO WHAT?” TEST

### What fact would I lead with at a dinner party of economists?

“I looked at fentanyl test strip legalization not by asking whether overdose deaths fell overall, but by asking whether deaths fell more for drugs that are actually at risk of hidden fentanyl contamination. The answer is: maybe directionally, but the cleaner takeaway is that the methadone negative control moves the wrong way, suggesting legalization proxies for a broader harm-reduction package rather than a pure information shock.”

That is the interesting fact.

### Would people lean in or reach for their phones?

A mixed reaction. The mechanism angle would get attention from applied micro people. The raw result being imprecise and somewhat null-ish lowers excitement. The methadone anomaly is the hook that saves it from total phone-reaching.

### What follow-up question would they ask?

Almost certainly: “So is the takeaway that test strips do not work, or that legalization is the wrong treatment variable because actual access and uptake are what matter?”

That is the question the paper must answer more clearly. Right now it risks being read as evidence on effectiveness when it is more plausibly evidence on the limits of legalization as a proxy for effective exposure.

### If the findings are null or modest, is the null itself interesting?

Potentially yes, but only if the paper makes the right case. The interesting null is not “we estimated zero.” The interesting null is:

- even in the subgroup where the informational mechanism should be strongest, population mortality effects are hard to detect from legalization alone;
- and the negative control suggests that policy bundling can produce misleading apparent effects.

That is valuable. But the paper must stop apologizing for the null and instead interpret it as evidence about what legalization can and cannot identify.

At the moment it still reads a bit like a failed attempt to find an effect. It needs to read like a successful attempt to test a mechanism and uncover the limits of the policy proxy.

---

## 6. STRUCTURAL SUGGESTIONS

### What would make it read better?

1. **Rewrite the introduction around the mechanism test.**  
   The first page should establish:
   - FTS are an information intervention.
   - Aggregate effects cannot validate the mechanism.
   - Drug-type heterogeneity provides the test.
   - The paper’s main substantive finding is the failure of a clean mechanism signal.

2. **Move some methodological throat-clearing later.**  
   The empirical strategy section is fine, but the paper currently overexplains the design relative to the novelty of the question. The reader should get to the main figure or table very quickly.

3. **Promote the negative control to the main contribution, not an auxiliary result.**  
   Right now the methadone result is buried as “diagnostic.” It may be the most interesting result in the paper. Bring it forward earlier in the introduction and in the results overview.

4. **Trim generic institutional background.**  
   The fentanyl crisis background is important but too standard. AER readers do not need several paragraphs of scene-setting before hearing the paper’s idea.

5. **Be careful with the robustness section.**  
   The paper spends a fair amount of space showing the null is still null. That is not very interesting. If any result in robustness changes the interpretation, it belongs in the main text; otherwise compress.

6. **The conclusion currently mostly summarizes.**  
   It should instead do one of two things:
   - extract the general lesson about mechanism testing under bundled policy adoption; or
   - articulate what evidence one would actually need to learn whether FTS save lives.

### Is the paper front-loaded with the good stuff?

Not enough. The good stuff is:
- mechanism versus aggregate effects;
- the drug-type comparison;
- the methadone negative control.

Those should all be on page 1.

### Are there buried results that should be in the main results?

The negative-control logic is already in the main results, but it should be elevated rhetorically. The psychostimulant placebo seems less central and can stay secondary unless the paper wants a contamination-risk gradient story.

### Should anything be shortened or moved?

Yes:
- shorten institutional background;
- shorten generic threats-to-validity discussion;
- shorten robustness prose;
- likely eliminate the standardized effect size appendix from the strategic narrative—it does not help sell the paper.

---

## 7. WHAT WOULD MAKE THIS AN AER PAPER?

Be honest: this is not yet an AER paper in current form.

### What is the gap?

Mostly **framing plus ambition**, with some **scope** concerns.

- **Framing problem:** The best idea in the paper is not the headline. The paper should be about mechanism identification for informational harm-reduction policies, not just FTS legalization and mortality.
- **Ambition problem:** It is a careful but safe exercise. It asks a reasonable question with available data, but the stakes remain modest because the treatment is legalization rather than access/use, and the outcome is a noisy distal endpoint.
- **Scope problem:** The paper needs either a broader conceptual payoff or richer evidence on behavior/mechanism to excite the field.
- **Novelty problem:** At present, many readers will see “another policy staggered-adoption paper on overdose outcomes.” The paper must actively prevent that reading.

### What would excite the top 10 people in this field?

One of two things:

1. **A much sharper conceptual paper on policy bundles and mechanism testing**  
   where the methadone result becomes the central lesson and the paper clearly teaches others how to interpret legal reforms that proxy for broader service expansion.

2. **A richer empirical paper linking legalization to actual uptake and behavior**  
   not just mortality. That would get much closer to the mechanism.

Without one of those, this remains more like a solid field-journal paper than a top general-interest paper.

### Single most impactful advice

**Reframe the paper around the failure of legalization to generate a clean information shock—and use the methadone negative control as the central insight about bundled harm-reduction policies, rather than presenting the paper as a mostly null mortality study.**

That one change would not solve everything, but it would immediately make the paper smarter, more general, and more memorable.

---

### Strategic Assessment

- **Current framing quality:** Needs rethinking
- **Contribution clarity:** Somewhat fuzzy
- **Literature positioning:** Could be stronger
- **Narrative arc:** Serviceable
- **AER distance:** Far
- **Single biggest improvement:** Recast the paper from “an imprecise estimate of FTS legalization on overdose deaths” to “a mechanism test showing that legalization is a bundled policy proxy, not a clean information shock.”